• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bicara Therapeutics Inc. - Common Stock (NQ:BCAX)

    17.32 -0.11 (-0.63%)
    Streaming Delayed Price Updated: 1:40 PM EST, Jan 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 134,831
    Open 17.34
    Bid (Size) 17.24 (100)
    Ask (Size) 17.40 (500)
    Prev. Close 17.43
    Today's Range 16.53 - 17.36
    52wk Range 7.800 - 19.71
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
    From Bicara Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +5.7%
    +5.7%
    1 Month
    -5.7%
    -5.7%
    3 Month
    -6.4%
    -6.4%
    6 Month
    +70.1%
    +70.1%
    1 Year
    +33.3%
    +33.3%

    More News

    Read More
    News headline image
    Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
    Via Investor Brand Network
    News headline image
    Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For
    From BioMedWire
    Via GlobeNewswire
    Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
    Via Investor Brand Network
    News headline image
    Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
    Via FinancialNewsMedia
    News headline image
    These stocks that are showing activity before the opening bell on Monday. ↗
    Via Chartmill
    News headline image
    Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    4 Biotech Stocks Seeing Explosive Momentum Gains ↗
    Via Benzinga
    Topics ETFs Stocks
    News headline image
    Bicara Therapeutics to Participate in Upcoming Investor Conferences
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
    From Bicara Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On? ↗
    Via Benzinga
    News headline image
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    News headline image
    Gold Gains Over 1%; Ross Stores Shares Dip After Pulling Fiscal 2026 Outlook ↗
    Via Benzinga
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    Nasdaq Down Over 1%; Workday Shares Tumble After Q1 Results ↗
    Via Benzinga

    Frequently Asked Questions

    Is Bicara Therapeutics Inc. - Common Stock publicly traded?
    Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Bicara Therapeutics Inc. - Common Stock trade on?
    Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?
    The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market
    What is the current price of Bicara Therapeutics Inc. - Common Stock?
    The current price of Bicara Therapeutics Inc. - Common Stock is 17.32
    When was Bicara Therapeutics Inc. - Common Stock last traded?
    The last trade of Bicara Therapeutics Inc. - Common Stock was at 01/13/26 01:40 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.